PMID- 34367283
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2021
DP  - 2021
TI  - A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial 
      Transition for Hepatocellular Carcinoma with Regard to Prognosis, 
      Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic 
      Efficacy, and Immunosuppressive Molecules.
PG  - 5033416
LID - 10.1155/2021/5033416 [doi]
LID - 5033416
AB  - PURPOSE: Mesenchymal-epithelial transition (MET), a reverse biological process to 
      epithelial-mesenchymal transition (EMT), is involved in tumor metastasis and 
      invasion. However, the role of MET-related genes (MRGs) in hepatocellular 
      carcinoma (HCC) prognosis remains unclear. METHODS: In this research, we obtained 
      MRGs data and clinical information from public databases. In the TCGA dataset, a 
      prognostic signature for HCC was constructed by the least absolute shrinkage and 
      selection operator (LASSO) method and externally verified using the ICGC dataset. 
      RESULTS: There were 148 differentially expressed MRGs (DEMRGs), out of which 37 
      MRGs were found associated with overall survival (OS) in the univariate Cox 
      analysis. A novel signature integrating of 5 MRGs was constructed, which split 
      patients into high- and low-risk groups. Kaplan-Meier analysis revealed that 
      high-risk patients had unfavorable OS than those low-risk counterparts. Receiver 
      operating characteristic curve (ROC) showed great performance of this signature 
      in predictive ability. Multivariate Cox analysis confirmed that this signature 
      could independently predict HCC prognosis. The analysis of immune cell 
      infiltration demonstrated that immune status varied differently between high- and 
      low-risk groups. The analysis of clinicopathological characteristics suggested 
      that tumor grade, clinical stage, and T stage were different between risk groups. 
      The analysis between this signature and chemotherapeutic efficacy and 
      immunosuppressive molecules indicated that this signature could serve as a 
      promising predictor. CONCLUSIONS: In conclusion, we constructed and verified a 
      novel signature from the perspective of MET, which was significantly associated 
      with HCC prognosis, clinicopathological features, immune status, chemotherapeutic 
      efficacy, and immunosuppressive biomarkers.
CI  - Copyright (c) 2021 Lijun Xu and Qing Zheng.
FAU - Xu, Lijun
AU  - Xu L
AUID- ORCID: 0000-0001-9515-6128
AD  - Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, 
      Inflammatory Bowel Disease Research Center, Shanghai Institute of Digestive 
      Disease, Division of Gastroenterology and Hepatology, Renji Hospital, School of 
      Medicine Shanghai Jiao Tong University, 160# Pu Jian Ave, Shanghai 200127, China.
FAU - Zheng, Qing
AU  - Zheng Q
AUID- ORCID: 0000-0001-8742-7629
AD  - Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, 
      Inflammatory Bowel Disease Research Center, Shanghai Institute of Digestive 
      Disease, Division of Gastroenterology and Hepatology, Renji Hospital, School of 
      Medicine Shanghai Jiao Tong University, 160# Pu Jian Ave, Shanghai 200127, China.
LA  - eng
PT  - Journal Article
DEP - 20210728
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC8342179
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/08/10 06:00
MHDA- 2021/08/10 06:01
PMCR- 2021/07/28
CRDT- 2021/08/09 06:31
PHST- 2021/05/06 00:00 [received]
PHST- 2021/06/30 00:00 [revised]
PHST- 2021/07/14 00:00 [accepted]
PHST- 2021/08/09 06:31 [entrez]
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2021/08/10 06:01 [medline]
PHST- 2021/07/28 00:00 [pmc-release]
AID - 10.1155/2021/5033416 [doi]
PST - epublish
SO  - J Oncol. 2021 Jul 28;2021:5033416. doi: 10.1155/2021/5033416. eCollection 2021.